NO inhalation
PreclinicalSmall molecule
NO inhalation is one of 76 small molecule programs targeting COVID-19. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Statins
SanofiPreclinical
Rayaldee
OOrganon and Co
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Disease-Modifying Anti-Rheumatic Drugs
RochePreclinical
Pfizer-COVID-19 Vaccine
ModernaPreclinical
Olokizumab
UCBPreclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NO inhalation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai Zhongshan Hospital